Artgen

Artgen is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Artgen balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Artgen cash flows

Report period2019 2020 2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Artgen multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Artgen profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Artgen assets
Artgen cash flows
Artgen dividends
2.14%

Artgen dividend policy

The recommended amount of dividend payments is determined based on year-end financial results, economic situation, and industry position and may range from 40% to 60% of net profit.

Artgen shares

TickerNameTypeNominal valueISINPrice
ABIO:RMArtgenCommon shareRUB 0.1RU000A0JNAB6RUB 76.3

Artgen bonds

NameIssue sizePriceYield
ISKJ BO-01 (RUB)300,000 pcs.79.9%24.90%
Share capital structure of Artgen
Artgen news
20.12.2024
Betuvax, part of the Artgen Biotech group, has raised about ₽100 million in venture capital investment in a private placement. Funds will be used to conduct preclinical and clinical studies of the drug against cat allergy, as well as to develop vaccines against human papillomavirus and rotavirus.
Source: {source} pictogram artgen.ru
Pictogram next
01.11.2024
Artgen Biotech's RAS net profit for 9 months of 2024 amounted to ₽220.7 million, up 3.5 times from ₽63.2 million in the previous year. Revenue rose 2.6 times to ₽114.9 million compared to ₽44.9 million a year earlier.
Source: {source} pictogram e-disclosure.ru
Pictogram next
11.10.2024
Artgen Biotech Group is investing in the development of a platform for creating new subunit vaccines based on surface recombinant proteins and spherical adjuvant particles. Developer of the technology platform is RBT, a company within the Artgen Biotech group. Total investment in the development of the production component of the platform by RBT, including f...
Source: {source} pictogram artgen.ru
Pictogram next
16.09.2024
Artgen will buy an additional ₽240 million of subsidiary Genetico. Genetico will use the raised funds to repay a bond issue.
Source: {source} pictogram artgen.ru
Pictogram next
All Artgen news
General information
Company nameArtgen
Tags#biotechnology, #pharmacy, #innovations of the russia
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websiteartgen.ru
Information disclosuree-disclosure.ru